SCHEMBL254857

SCHEMBL254857

CC1CCC(C(F)(F)F)CC1

nearest known ligand 0.30

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.30
NOS1 P29475 1/20 0.30
NOS2 P35228 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL436504 1.00 NOS3 (0.30) NOS3NOS1NOS2
SCHEMBL436177 1.00 NOS3 (0.30) NOS3NOS1NOS2
SCHEMBL21638056 0.92
SCHEMBL9613616 0.92
SCHEMBL23432355 0.89
SCHEMBL999487 0.85 EPHX1 (0.32)
SCHEMBL13480367 0.85 LIPA (0.32)
SCHEMBL18060 0.83
SCHEMBL1035408 0.83 NOS3 (0.36) NOS3NOS1NOS2
SCHEMBL8791023 0.82 L3MBTL1 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 508 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4347597-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND FOR THE TREATMENT OF DERMAL DISORDERS Otsuka Pharmaceutical Co., Ltd. (JP) 2024-04-10 EP claimed
US-20230278958-A1 TRICYCLIC HETEROCYCLES MERCK PATENT GMBH (DE) 2023-09-07 US claimed
US-20230174538-A1 Tricyclic heterocycles MERCK PATENT GMBH (DE) 2023-06-08 US claimed
EP-4185564-A1 TRICYCLIC HETEROCYCLES Merck Patent GmbH (DE) 2023-05-31 EP claimed
WO-2023078813-A1 HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS MERCK PATENT GMBH (DE) 2023-05-11 WO claimed
EP-4146652-A1 TRICYCLIC HETEROCYCLES USEFUL AS TEAD BINDERS Merck Patent GmbH (DE) 2023-03-15 EP claimed
CN-115515959-A Tricyclic heterocycles as TEAD binders 默克专利股份公司 2022-12-23 CN claimed
WO-2022255408-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND FOR THE TREATMENT OF DERMAL DISORDERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2022-12-08 WO claimed
WO-2021224291-A1 TRICYCLIC HETEROCYCLES USEFUL AS TEAD BINDERS MERCK PATENT GMBH (DE) 2021-11-11 WO claimed
WO-2013153535-A1 TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS GLENMARK PHARMACEUTICALS S.A. (CH) 2013-10-17 WO claimed
WO-2011033225-A2 SUBSTITUTED 3-AMINO-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-24 WO claimed
EP-4400172-A2 PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS Incyte Holdings Corporation (US) 2024-07-17 EP disclosed
US-12041846-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2024-07-16 US disclosed
US-12035613-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2024-07-09 US disclosed
US-20240224782-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2024-07-04 US disclosed
WO-2004100875-A2 BENZIMIDAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK & CO., INC. (US) 2004-11-25 WO disclosed
US-5281625-A Benzyl substituted guanidine derivatives, salts, and metal complexes BASF AKTIENGESELLSCHAFT (DE) 1994-01-25 US disclosed
EP-0534501-A2 Fungicidal guanidines BASF Aktiengesellschaft (DE) 1993-03-31 EP disclosed
US-5126374-A For plants, seeds, soils, effective at low concentrations BASF AKTIENGESELLSCHAFT (DE) 1992-06-30 US disclosed
EP-0406699-A2 Fungicidal guanidines BASF Aktiengesellschaft (DE) 1991-01-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278958-A1 TRICYCLIC HETEROCYCLES YAP1, TERF2IP, TEAD1 NOS3 3864/4885NOS1 3802/4885NOS2 3931/4885
US-12041846-B2 Organic electroluminescent materials and devices OCIAD1, OSBP, OCIAD2 NOS3 1283/4885NOS1 651/4885NOS2 1031/4885
US-20230174538-A1 Tricyclic heterocycles YAP1, TEAD1, TERF2IP NOS3 3974/4885NOS1 3856/4885NOS2 3951/4885
US-12035613-B2 Organic electroluminescent materials and devices OCIAD2, OCIAD1, OTC NOS3 1755/4885NOS1 1374/4885NOS2 1621/4885
US-20240224782-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES RER1, OCIAD2, OCIAD1 NOS3 2335/4885NOS1 665/4885NOS2 1188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.